<DOC>
	<DOCNO>NCT00005991</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness gemcitabine liposomal doxorubicin treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Gemcitabine Liposomal Doxorubicin Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate , duration response , time disease progression , duration survival woman metastatic breast cancer treat gemcitabine doxorubicin HCl liposome . II . Determine qualitative quantitative toxicity reversibility toxicity treatment regimen patient . OUTLINE : Patients receive gemcitabine intravenous ( IV ) 30 minute day 1 8 doxorubicin HCl liposome IV 2.5 hour day 1 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow 3 week . PROJECTED ACCRUAL : A total 22-46 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable disease No uncontrolled brain metastasis leptomeningeal disease Brain metastasis treat surgery and/or radiotherapy allow neurologic status stable two week last dose dexamethasone Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin great 1.2 mg/dL SGPT le 1.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF least 50 % MUGA No cardiac disease congestive heart failure Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious illness , psychiatric disorder , active infection No prior concurrent malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior highdose chemotherapy follow bone marrow transplantation Chemotherapy : See Biologic Therapy At least 3 week since prior chemotherapy recover No prior doxorubicin HCl liposome gemcitabine Prior neoadjuvant chemotherapy allow At least 12 month since prior adjuvant anthracyclinebased therapy evidence anthracycline resistance ( i.e. , develop progressive disease receive adjuvant therapy within 6 month complete adjuvant therapy ) Prior mitoxantrone allow total dose great 105 mg/m2 IV bolus 140 mg/m2 IV continuous infusion Prior doxorubicin allow total dose great 300 mg/m2 IV bolus 400 mg/m2 IV continuous infusion No prior chemotherapy metastatic disease Endocrine therapy : Prior adjuvant and/or palliative hormonal therapy allow Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery : See Disease Characteristics Prior surgery allow Other : At least 3 week since prior investigational study Concurrent pamidronate allow bone site disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>